Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
CVS, HUM, and UNH: Weighing Momentum Across Managed Care Stocks

CVS, HUM, and UNH: Weighing Momentum Across Managed Care Stocks

Key Takeaways

  • CVS is showing the clearest fundamental momentum, with recent operating income growth accelerating sharply on an Aetna and Medicare Advantage margin recovery.
  • HUM is absorbing a sizable near-term earnings headwind from Medicare Stars ratings, even as its 2026 membership growth has been strong.
  • UNH is the largest and most diversified of the three but has faced the steepest sentiment reset, including rising medical costs and regulatory scrutiny.
  • Relative performance and market positioning diverge sharply: CVS trades at a low forward earnings multiple, HUM carries a thin profit margin, and UNH offers scale but uncertain near-term catalysts.
  • Tickeron AI Verdict: Based on trend consistency, stability, and catalysts, the AI would currently favor CVS among the three.

Setting the Stage

CVS Health, HUM, and UNH remain three of the most closely followed names in U.S. managed care, yet each operates from a distinct position. This comparison matters for investors looking at Medicare Advantage, pharmacy services, and broader healthcare exposure while balancing growth potential against risk. All three face similar pressures from elevated medical costs, reimbursement challenges, and regulatory shifts, but their recent trajectories and positioning have moved in different directions. Clarifying those differences can point to which name currently shows the most consistent trend and the clearest path forward.

CVS Health: Building Momentum

CVS (CVS Health Corporation) runs a broad platform that includes retail pharmacy, a pharmacy benefits manager, and the Aetna insurance business. After a challenging 2024, sentiment has turned more constructive in recent quarters. With new leadership in place, the focus has been on stabilizing the healthcare benefits segment and restoring margins in Medicare Advantage. In recent trading, CVS has hovered near the low-$80s, with a market capitalization around $110 billion and a forward P/E near 10. Latest quarterly revenue rose about 5% year over year, while operating income grew sharply, helped by better medical cost management and early restructuring progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Analysts have pointed to GLP-1 support programs and a steadier policy environment as additional positives.

Humana: Growth Offset by Near-Term Pressure

HUM (Humana Inc.) ranks as the second-largest Medicare Advantage insurer and runs the CenterWell services business focused on primary care, pharmacy, and home health. The company posted solid full-year 2025 adjusted earnings, yet its 2026 guidance reflects an approximately $3.5 billion headwind from lower Medicare Stars quality ratings that reduce bonus payments. Near-term earnings expectations sit well below prior-year levels, and profit margins remain thin at roughly 1% of revenue. On the brighter side, Humana added about one million members during the recent Annual Enrollment Period. The stock has traded near the mid-$170s recently, reflecting the balance between strong enrollment gains and margin compression ahead.

UnitedHealth Group: Scale With More Uncertainty

UNH (UnitedHealth Group Incorporated) is the largest U.S. health insurer and operates the diversified Optum platform across care delivery, pharmacy, and analytics. It has encountered the most turbulence of the three, with higher medical costs, a Department of Justice investigation into Medicare Advantage billing, and a leadership change all affecting sentiment over the past year. After a significant drawdown, shares have stabilized and recovered somewhat, aided by a disclosed Berkshire Hathaway stake and management actions to reprice plans and protect margins. UNH has also exited selected Medicare Advantage markets to support profitability. Its scale and multiple revenue streams remain key strengths, though near-term catalysts appear less defined than for peers showing clearer margin improvement.

Side-by-Side Positioning

The three differ in business mix and risk exposure. CVS offers the most vertical integration across pharmacy, PBM economics, and insurance, providing diversification alongside regulatory exposure on drug pricing. HUM represents the purest play on Medicare Advantage, with direct sensitivity to senior demographics and Stars ratings. UNH combines the largest insurance portfolio with the expanding Optum platform, delivering scale and revenue diversity, yet its performance has lagged amid the broader reset. Valuation-wise, CVS sits at the lowest forward multiple, HUM operates with thin margins that magnify cost changes, and UNH carries ongoing legal and cost-trend questions. Recent momentum appears strongest at CVS, while HUM offers a longer-term recovery narrative and UNH presents a stabilizing but less certain path.

Exploring AI-Driven Trading Approaches

In my own research process, I often review Tickeron’s Trending AI Robots to see which strategies are performing best in the current environment. The page highlights bots with strong recent results across different styles and timeframes, complete with historical data and the specific tickers they target. It helps narrow down AI-driven options that align with today’s market dynamics without requiring constant manual screening.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HUM, UNH, CVS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HUM's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for HUM moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 21 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUM as a result. In 47 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

The Moving Average Convergence Divergence Histogram (MACD) for HUM turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

HUM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 224 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

HUM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company offers health insurance coverage and related services

Industry ManagedHealthCare

Industry
Managed Health Care
Address
101 East Main Street
Phone
+1 502 580-1000
Employees
67060
Web
https://www.humana.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.